Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors
About the study
Who can take part
INCLUSION CRITERIA
Key Inclusion Criteria:
EXCLUSION CRITERIA
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
For Part 1 and 2:
- Histological or cytological documentation of a solid tumor that is metastatic or unresectable via a pathology report.
- CLDN6-positive tumor sample as assessed by central laboratory testing using a validated immunohistochemistry (IHC) assay in formalin-fixed paraffin-embedded neoplastic tissues or alternatively from fresh tissue if archival tissue is unavailable. If archival tissue samples from several points of time are available, the most recent one is preferred.
- Measurable disease per RECIST 1.1 (measurable per RECIST 1.1 or evaluable per GCIG criteria for ovarian tumors).
For Part 1 (Dose escalation):
* Patients with advanced/metastatic ovarian (including fallopian tube and peritoneal), non-squamous NSCLC, endometrial, or testicular cancer, for whom there is no available standard therapy likely to confer clinical benefit, or the patient is not a candidate for such available therapy, or patients with not otherwise specified (NOS) tumors (as confirmed by histological diagnosis), rare tumors (defined as those occurring in <15 out of 100,000 people each year as per National Cancer Institute [NCI] guidelines) and cancers of unknown primary, not included in the pre-defined eligible tumor types. Patients must have received all available standard therapies, including targeted therapies based on mutation status (per guidelines from the US Food and Drug Administration [FDA], American Society of Clinical Oncology [ASCO], European Society for Medical Oncology [ESMO] or local guidelines used at the site), and failed at least first line standard of care therapy prior to enrollment.
Key Exclusion Criteria:
- Chemotherapy, or molecularly-targeted agents within 3 weeks or 5 half-lives (whichever is longer) of the start of study treatment; immunotherapy/monoclonal antibodies within 3 weeks of the start of study treatment; nitrosoureas, antibody-drug conjugates, or radioactive isotopes within 6 weeks of the start of study treatment.
- Radiotherapy in the last 6 weeks prior to the first dose of BNT142 (excluding brain radiotherapy for which 3 weeks prior to the first dose of BNT142 is allowed). Previously irradiated tumor lesions cannot be considered as target lesions or non-target lesions in this study.
- Concurrent systemic (oral or intravenous [IV]) steroid therapy >10 mg prednisone daily or its equivalent for an underlying condition apart from physiologic corticosteroid replacement therapy.
- Major surgery within 4 weeks before the first dose of BNT142.
- Ongoing or active infection requiring IV treatment with anti-infective therapy that has been administered less than 2 weeks prior to the first dose of BNT142.
- Prior treatment with a CLDN6 targeting therapy.
- Side effects of any prior therapy or procedures for any medical condition not recovered to National Cancer Institute Common Terminology Criteria for Adverse Events v.5 Grade ≤1, except for anorexia, fatigue, hyperthyroidism, hypothyroidism, and peripheral neuropathy, which must have recovered to Grade ≤2. Alopecia of any grade is allowed.
- Current evidence of new or growing brain or leptomeningeal metastases during screening. Patients with known brain metastases may be eligible if they:
- Had radiotherapy, surgery or stereotactic surgery for the brain metastases;
- Have no neurological symptoms (excluding Grade ≤2 neuropathy);
- Have stable brain metastasis on the computer tomography (CT) or magnetic resonance imaging (MRI) scan within 4 weeks before signing the informed consent form; and
- Are not undergoing acute corticosteroid therapy or steroid taper.
- Notes: Patients with central nervous system symptoms should undergo a CT scan or MRI of the brain to exclude new or progressive brain metastases. Spinal bone metastases are allowed, unless imminent fracture with cord compression is anticipated.
- Pregnant or breastfeeding or planning to get pregnant within 6 months of the last dose of BNT142.
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Study Details
Contition
Solid Tumor
Age
18+
Phase
PHASE1/PHASE2
Participants Needed
330
Est. Completion Date
Apr 30, 2026
Treatment Type
INTERVENTIONAL
Sponsor
BioNTech SE
ClinicalTrials.gov NCT Identifier
NCT05262530
Study Number
BNT142-01
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?